首页 | 本学科首页   官方微博 | 高级检索  
     


Drug decriminalization and the price of illicit drugs
Affiliation:1. Nova School of Business and Economics, Universidade Nova de Lisboa, Campus de Campolide, 1099-032 Lisbon, Portugal;2. Banco de Portugal, Portugal;1. CHIP, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark;2. Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain;3. Cermes3, Inserm U988/CNRS UMR 8211, EHESS, Paris Descartes University, Paris, France;4. Clinic for Infectious Diseases and Febrile Illnesses, University Medical Centre Ljubljana, Ljubljana, Slovenia;5. European Liver Patients’ Association, Brussels, Belgium;6. Correlation Network, Amsterdam, the Netherlands;7. European AIDS Treatment Group, Brussels, Belgium;8. Department of Social and Environmental Health Research, London School of Hygiene and Tropical Medicine, London, United Kingdom;1. Department of Social and Preventive Medicine, School of Public Health, Université de Montréal, 7101 Avenue du Parc, Montréal, QC H3N 1X9, Canada;2. Research Centre, Centre Hospitalier de l’Université de Montréal (CRCHUM), 900 Saint-Denis, Montréal, QC H2X 0A9, Canada;3. School of Population Health, Division of Health Sciences, University of South Australia, GPO Box 2471, Adelaide, SA 5001, Australia;4. Department of Medicine, St. Vincent’s Hospital, The University of Melbourne, 29 Regent Street, Fitzroy, VIC 3065, Australia;5. Department of Family and Emergency Medicine, Faculty of Medicine, Université de Montréal, C.P. 6128, Succursale Centre-Ville, Montréal, QC H3C 3J7, Canada;6. Department of Psychiatry, Faculty of Medicine, Université de Montréal, C.P. 6128, Succursale Centre-Ville, Montréal, QC H3C 3J7, Canada;7. Department of Family Medicine, Faculty of Medicine, McGill University, 5858 Côte-des-Neiges, Montréal, QC H3S 1Z1, Canada;1. The Kirby Institute, UNSW Sydney, Sydney, Australia;2. CHUM Research Centre (CRCHUM), Centre Hospitalier de l’Université de Montréal, Montréal, Canada;3. Department of Family and Emergency Medicine, Faculty of Medicine, Université de Montréal, Montréal, Canada;4. CHIP, Rigshospitalet, University of Copenhagen, Denmark;5. Barcelona Institute of Global Health (ISGlobal), Hospital Clínic, Barcelona, Spain;6. Department of Infectious Diseases, Akershus University Hospital, Lørenskog, Norway;7. Arud Centres of Addiction Medicine, Zurich, Switzerland;8. Centre for Social Research in Health, UNSW Sydney, Sydney, Australia;9. School of Social & Community Medicine, University of Bristol, Bristol, United Kingdom;10. Disease Elimination Program, Burnet Institute, Melbourne, Australia;11. Médecins sans Frontières, Geneva, Switzerland;12. Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, Sydney, Australia;13. Institute for Clinical Medicine, University of Oslo, Norway;14. Department of Gastroenterology, Oslo University Hospital, Norway;15. National Drug and Alcohol Research Centre, UNSW Australia, Sydney, Australia;p. University of Helsinki, Helsinki, Finland;q. National Institute for Health and Welfare, Helsinki, Finland;r. Australian Injecting & Illicit Drug Users League, Canberra, Australia;s. Ninewells Hospital and Medical School, Dundee, United Kingdom;t. Toronto Centre for Liver Disease, Sandra Rotman Centre for Global Health, University of Toronto, Toronto, Canada;u. The Liver Unit, Queen Mary University of London, London, United Kingdom;v. School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, United Kingdom;w. Health Protection Scotland, Glasgow, United Kingdom;x. Centre for Interdisciplinary Addiction Research, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany;y. Department of Gastroenterology and Hepatology, Ziekenhuis Oost Limburg, Genk, Belgium;z. Department of Hepatology, UZ Leuven, Leuven, Belgium;1. Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium;2. Institute of Neuropsychiatry & Addictions-Hospital del Mar, IMIM (Hospital del Mar Medical Research Institute), Universitat Autònoma de Barcelona, Barcelona, Spain;3. Spectrum CIC, Wakefield, United Kingdom;4. Division of General Internal Medicine, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, United States;5. University of Oslo, Oslo, Norway;6. Abdominal Center, Helsinki University Hospital, Helsinki, Finland;7. Santa Chiara University Hospital, University of Pisa, Italy;1. New York University College of Global Public Health, New York, NY, USA;2. Center for Drug Use and HIV Research, New York University, New York, NY, USA;3. Center for Health, Identity, Behavior, and Prevention Studies, New York University, New York, NY, USA;4. Ukrainian Institute on Public Health Policy, Kiev, Ukraine;5. National University of Kyiv-Mohyla Academy, Kiev, Ukraine;6. Alliance for Public Health (Formerly ICF International HIV/AIDS Alliance in Ukraine), Kiev, Ukraine;7. SUNY Downstate Medical Center, Department of Medicine, Brooklyn, NY, USA
Abstract:BackgroundThis study is an empirical assessment of the impact of the drug decriminalization policy followed by Portugal in July 2001, on the price of illicit drugs.MethodsThe analysis is performed using a difference-in-differences approach and the Synthetic Control Method in order to construct a synthetic control unit from a convex combination of countries.ResultsThe results suggest that the prices of opiates and cocaine in the post-treatment period did not decrease in the sequence of the policy change.ConclusionWe conclude that the drug decriminalization policy seems to have caused no harm through lower illicit drugs prices, which would lead to higher drug usage and dependence.
Keywords:Illicit drugs  Drug decriminalization policy  Drug prices  Treatment effects
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号